UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

Veru Inc.

Veru Inc.

MIAMI, July 25, 2022 (Globe NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical firm concentrated on developing novel medicines for COVID-19 and other viral and ARDS-related ailments and for the administration of breast and prostate cancers, these days declared that the United Kingdom’s (UK’s) Medicines and Healthcare Solutions Regulatory Agency (MHRA) considers that the currently available security and efficacy info will assist an expedited overview of the promoting authorization application for the Company’s sabizabulin treatment method in hospitalized COVID-19 sufferers at large risk for Acute Respiratory Distress Syndrome (ARDS) when the software is submitted.

“We are happy that the MHRA has agreed to guidance the expedited overview of our sabizabulin British isles promoting authorization submission. With this choice, we prepare to commence towards the submission of our application as soon as achievable,” stated Mitchell Steiner, M.D., Chairman, President, and Main Govt Officer of Veru. “COVID infections are sharply increasing in the United kingdom. Regrettably, the death fee in hospitalized patients with reasonable to severe COVID-19 who are at chance for ARDS remains unacceptably significant with existing regular of treatment. By decreasing fatalities in hospitalized COVID-19 people, sabizabulin has terrific potential to participate in a important job in the struggle in opposition to COVID-19 in the British isles and somewhere else.”

About Veru Inc.
Veru is a biopharmaceutical company centered on acquiring novel medications for COVID-19 and other viral and ARDS-similar illnesses and for the management of breast and prostate cancers.

Infectious ailment program:

The Firm has concluded a good Section 3 COVID-19 analyze in hospitalized moderate to serious COVID-19 people at high chance for ARDS.

A double-blind, randomized, placebo-managed Section 3 COVID-19 clinical demo was performed in around 210 hospitalized COVID-19 patients with reasonable to intense COVID (≥ WHO 4-supplemental oxygen) at significant chance for ARDS and death. The key endpoint was the proportion of fatalities by Working day 60. Based on a prepared interim assessment of the very first 150 sufferers randomized, the Impartial Knowledge Checking Committee unanimously halted the study for frustrating efficacy and safety. Cure with sabizabulin 9mg when day-to-day, an oral, first-in-class, new chemical entity, microtubule disruptor that has twin anti-inflammatory and antiviral houses, resulted in a clinically meaningful and statistically substantial 55.2{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} relative reduction in deaths. On June 7, 2022, the Firm submitted a ask for for unexpected emergency use authorization to Fda. On July 6, 2022, the Corporation introduced the publication of the Section 3 COVID-19 demo outcomes assessing the efficacy and security of oral sabizabulin in The New England Journal of Drugs Evidence®.

Oncology plan:

The Company’s late-phase breast most cancers progress portfolio comprises enobosarm, a selective androgen receptor focusing on agonist, and sabizabulin.

Recent scientific tests on the two drugs incorporate:

  • Enrolling Phase 3 ARTEST review of enobosarm in androgen receptor optimistic, estrogen receptor positive, and human epidermal advancement element receptor two detrimental (AR+ ER+ HER2-) metastatic breast most cancers with AR ≥ 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (third-line metastatic placing), and which has been granted Fast Track designation by the Fda.

  • Enrolling Phase 3 ENABLAR-2 research of enobosarm + abemaciclib (a CDK 4/6 inhibitor) combination in AR+ ER+ HER2- metastatic breast cancer with AR ≥ 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (2nd-line metastatic placing). The Organization and Eli Lilly and Enterprise have entered into a clinical research collaboration and provide arrangement for the ENABLAR-2 review. Lilly will supply Verzenio® (abemaciclib).

  • Planned Section 2b research of sabizabulin in AR+ ER+ HER2- metastatic breast cancer with AR < 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (third-line metastatic setting).

Veru’s late-stage prostate cancer portfolio comprises sabizabulin, VERU-100, a long-acting GnRH antagonist, and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.

Current studies on these drugs include:

  • Enrolling Phase 3 VERACITY study in metastatic castration and androgen receptor targeting agent resistant prostate cancer prior to IV chemotherapy.

  • Enrolling Phase 2 dose-finding study of VERU-100 in advanced hormone sensitive prostate cancer.

  • Planned Phase 2b study of zuclomiphene citrate to treat hot flashes in men with advanced prostate cancer undergoing androgen deprivation therapy.

Commercial sexual health program, Urev, has 2 FDA approved products:

  • ENTADFI™ (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia, for which commercialization launch plans are underway.

  • FC2 Female Condom® (internal condom), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections which is sold in the U.S. and globally.

Forward-Looking Statements
The statements in this release that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding: whether and when the Company will receive an emergency use authorization or any approval from FDA or MHRA or from any other regulatory authority outside the U.S. for sabizabulin for certain COVID-19 patients whether and when sabizabulin will become an available treatment option for certain COVID-19 patients in the U.S., UK or anywhere else outside the U.S. whether and when the Company will submit a marketing authorization application for sabizabulin to MHRA’ whether the Company will have sufficient supply of sabizabulin to meet demand, if an emergency use authorization or other approval is granted in the U.S. or in any other country whether the Company will secure any advance purchase agreement with the U.S. government or any foreign government whether the current and future clinical development and results will demonstrate sufficient efficacy and safety and potential benefits to secure FDA approval of the Company’s drug candidates and companion diagnostic whether the drug candidates will be approved for the targeted line of therapy the anticipated design and scope of clinical studies and FDA acceptance of such design and scope whether any regulatory pathways, including the accelerated Fast Track designations, to seek FDA approval for sabizabulin, enobosarm or any of the Company’s drug candidates are or continue to be available whether the expected commencement and timing of the Company’s clinical studies, including the Phase 3 ARTEST study, the Phase 3 ENABLAR-2 study, the sabizabulin monotherapy Phase 2b clinical study for 3rd line treatment of metastatic breast cancer, the Phase 2 registration clinical study for VERU-100, and the development of the companion diagnostic will be met when clinical results from the ongoing clinical studies will be available, whether sabizabulin, enobosarm, VERU-100, zuclomiphene, and ENTADFI will serve any unmet need or, what dosage, if any, might be approved for use in the U.S. or elsewhere, and also statements about the potential, timing and efficacy of the rest of the Company’s development pipeline, and the timing of the Company’s submissions to FDA and MHRA and FDA’s and MHRA’s review of all such submissions whether the companion diagnostic for enobosarm will be developed successfully or be approved by the FDA for use and whether and when ENTADFI will be commercialized successfully. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development the ability to enroll sufficient numbers of subjects in clinical studies and the ability to enroll subjects in accordance with planned schedules the ability to fund planned clinical development the timing of any submission to the FDA, MHRA or any other regulatory authority and any determinations made by the FDA, MHRA or any other regulatory authority the possibility that as vaccines and other antiviral medicines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated government entities possibly taking actions that directly or indirectly have the effect of limiting opportunities for sabizabulin as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments the Company’s existing products and any future products, if approved, possibly not being commercially successful the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical studies, supply chain and other third-party providers, commercial efforts, and business development operations the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations demand for, market acceptance of, and competition against any of the Company’s products or product candidates new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes risks relating to the Company’s development of its own dedicated direct to patient telemedicine and telepharmacy services platform, including the Company’s lack of experience in developing such a platform, potential regulatory complexity, and development costs the Company’s ability to protect and enforce its intellectual property the potential that delays in orders or shipments under government tenders or the Company’s U.S. prescription business relating to the FC2 female condom could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector for its FC2 female condom the concentration of accounts receivable with our largest customers and the collection of those receivables the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply any of its product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions costs and other effects of litigation, including product liability claims the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives the Company’s ability to successfully integrate acquired businesses, technologies or products and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the fiscal year ended September 30, 2021 and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at The Company disclaims any intent or obligation to update these forward-looking statements.

Verzenio® is a registered trademark of Eli Lilly and Company

NEJM Evidence® is a registered trademark of the Massachusetts Medical Society

Investor and Media Contact:

Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: [email protected]